真实世界中三尖瓣缘对缘修复的短期结局
bRIGHT 研究为前瞻性、单臂、开放标签、多中心上市后注册研究,在欧洲26个中心纳入接受 TriClip 系统治疗的重度三尖瓣反流患者。30天时99%成功植入器械、77%反流降至中度及以下,NYHA 分级与生活质量显著改善,2.5%发生主要不良事件。
要点
- 真实世界中三尖瓣缘对缘修复器械植入成功率高,30天反流显著降低。
- 术后30天心功能分级与生活质量评分均显著改善。
- 30天主要不良事件发生率低,提示手术安全性可接受。
核心结论
- 在多样化的真实世界人群中,经导管三尖瓣修复治疗显著三尖瓣反流安全有效。
研究设计与样本
- bRIGHT 为前瞻性、单臂、开放标签、多中心上市后注册研究,在欧洲26个中心开展。
- 纳入接受 TriClip 系统治疗的患者,超声心动图由核心实验室评估。
主要发现
- 99%患者成功植入器械,30天时77%三尖瓣反流降至中度及以下。
- 30天 NYHA I/II 级比例由20%升至79%(P < 0.0001)。
- 30天 KCCQ 评分改善19±23分(P < 0.0001)。
- 排除基线反流等级后,较小右房容积和较小拴系距离是出院时反流降至中度及以下的独立预测因素(OR: 0.679; 95% CI: 0.537-0.858; P = 0.0012;OR: 0.722; 95% CI: 0.564-0.924; P = 0.0097)。
临床怎么用
- 对于高龄、合并症多且症状明显的重度三尖瓣反流患者,TriClip 治疗可作为改善反流与症状的选项。
- 基线右房容积较小、拴系距离较小的患者更可能实现反流显著降低。
局限性
- 研究为单臂、开放标签设计,缺乏对照组。
- 随访时间仅30天,为短期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe tricuspid regurgitation (TR) is known to be associated with substantial morbidity and mortality. OBJECTIVES: The authors sought to study the acute outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair with the TriClip system (Abbott) in a contemporary, real-world setting. METHODS: The bRIGHT (An Observational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device) postapproval study is a prospective, single-arm, open-label, multicenter, postmarket registry conducted at 26 sites in Europe. Echocardiographic assessment was performed at a core laboratory. RESULTS: Enrolled subjects were elderly (79 ± 7 years of age) with significant comorbidities. Eighty-eight percent had baseline massive or torrential TR, and 80% of subjects were in NYHA functional class III or IV. Successful device implantation occurred in 99% of subjects, and TR was reduced to ≤moderate at 30 days in 77%. Associated significant improvements in NYHA functional class (I/II, 20% to 79%; P < 0.0001) and Kansas City Cardiomyopathy Questionnaire score (19 ± 23 points improvement; P < 0.0001) were observed at 30 days. With baseline TR grade removed as a variable, smaller right atrial volume and smaller tethering distance at baseline were independent predictors of TR reduction to ≤moderate at discharge (OR: 0.679; 95% CI: 0.537-0.858; P = 0.0012; OR: 0.722; 95% CI: 0.564-0.924; P = 0.0097). Fourteen subjects (2.5%) experienced a major adverse event at 30 days. CONCLUSIONS: Transcatheter tricuspid valve repair was found to be safe and effective in treating significant TR in a diverse, real-world population. (An Observational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device [bRIGHT]; NCT04483089).
引用
- Lurz P, Besler C, Schmitz T, et al. Short-Term Outcomes of Tricuspid Edge-to-Edge Repair in Clinical Practice. J Am Coll Cardiol. 2023. PMID: 37207923. doi:10.1016/j.jacc.2023.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。